Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal eventsMitchell R. Smith, Karim Fizazi, Robert E. Coleman et al.|Annals of Oncology|2014Cited by 145
Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Ji Xi et al.|European Urology|2018Cited by 93
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013).Juanita Crook, Laurence Klotz, Padraig Warde et al.|Journal of Clinical Oncology|2011Cited by 51
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen Kalapara, Artitaya Lophatananon, Jan Verbeek et al.|European Urology Oncology|2019Cited by 37
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumByung Ha Chung, Weiyu Li, Daan Nieboer et al.|European Urology Open Science|2022Cited by 27